IL273384B2 - Methods to prevent methionine oxidation in immune conjugates - Google Patents
Methods to prevent methionine oxidation in immune conjugatesInfo
- Publication number
- IL273384B2 IL273384B2 IL273384A IL27338420A IL273384B2 IL 273384 B2 IL273384 B2 IL 273384B2 IL 273384 A IL273384 A IL 273384A IL 27338420 A IL27338420 A IL 27338420A IL 273384 B2 IL273384 B2 IL 273384B2
- Authority
- IL
- Israel
- Prior art keywords
- ala
- val
- seq
- amino acid
- phe
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims 20
- 238000000034 method Methods 0.000 title claims 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title claims 11
- 229930182817 methionine Natural products 0.000 title claims 11
- 230000003647 oxidation Effects 0.000 title claims 4
- 238000007254 oxidation reaction Methods 0.000 title claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 229910006069 SO3H Inorganic materials 0.000 claims 8
- 108010056243 alanylalanine Proteins 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 6
- 230000003078 antioxidant effect Effects 0.000 claims 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 5
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 claims 3
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 3
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 3
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 claims 3
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 claims 3
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 claims 3
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 claims 3
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 3
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 claims 3
- -1 D-Phe-Phe-Lys Chemical compound 0.000 claims 3
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 claims 3
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 claims 3
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 claims 3
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 3
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 claims 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 3
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 3
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 3
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 claims 3
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 3
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 claims 3
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 claims 3
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 claims 3
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 claims 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 3
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims 3
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 claims 3
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 claims 3
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 3
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 108010068380 arginylarginine Proteins 0.000 claims 3
- 108010036533 arginylvaline Proteins 0.000 claims 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 3
- 108010054155 lysyllysine Proteins 0.000 claims 3
- 108010024607 phenylalanylalanine Proteins 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 3
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 claims 3
- 108010073969 valyllysine Proteins 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000012537 formulation buffer Substances 0.000 claims 2
- 229940099459 n-acetylmethionine Drugs 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562049P | 2017-09-22 | 2017-09-22 | |
| US201762573322P | 2017-10-17 | 2017-10-17 | |
| US201862712584P | 2018-07-31 | 2018-07-31 | |
| PCT/US2018/052197 WO2019060707A1 (en) | 2017-09-22 | 2018-09-21 | METHODS FOR PREVENTING OXIDATION OF METHIONINE IN IMMUNOCONJUGATES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273384A IL273384A (en) | 2020-05-31 |
| IL273384B1 IL273384B1 (en) | 2023-08-01 |
| IL273384B2 true IL273384B2 (en) | 2023-12-01 |
Family
ID=63794732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273384A IL273384B2 (en) | 2017-09-22 | 2018-09-21 | Methods to prevent methionine oxidation in immune conjugates |
| IL304551A IL304551A (en) | 2017-09-22 | 2023-07-18 | Methods to prevent methionine oxidation in immune conjugates |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304551A IL304551A (en) | 2017-09-22 | 2023-07-18 | Methods to prevent methionine oxidation in immune conjugates |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190111147A1 (ru) |
| EP (2) | EP4374850A2 (ru) |
| JP (2) | JP7203834B2 (ru) |
| KR (1) | KR20200070254A (ru) |
| CN (2) | CN111372610B (ru) |
| AU (1) | AU2018335780A1 (ru) |
| CA (1) | CA3075896A1 (ru) |
| IL (2) | IL273384B2 (ru) |
| MA (1) | MA50266A (ru) |
| SG (1) | SG11202002116YA (ru) |
| TW (1) | TW201919711A (ru) |
| WO (1) | WO2019060707A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3313884T2 (ro) * | 2015-06-29 | 2021-04-30 | Immunogen Inc | Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora |
| JP2022533009A (ja) * | 2019-04-29 | 2022-07-21 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| CA3149683A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010030670A2 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
| WO2017004026A1 (en) * | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Anti-cd 123 antibodies and conjugates and derivatives thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| US20100030670A1 (en) * | 2008-08-04 | 2010-02-04 | Mastercard International, Inc. | Method of monitoring different debit card transactions associated with a single funding source |
| JP2010241718A (ja) | 2009-04-03 | 2010-10-28 | Kyowa Hakko Kirin Co Ltd | 安定な抗体の水溶液製剤 |
| TW201501724A (zh) | 2013-03-15 | 2015-01-16 | Glaxosmithkline Ip No 2 Ltd | 低濃度抗體調配物 |
| JP6517468B2 (ja) * | 2014-01-10 | 2019-05-22 | 日本電気株式会社 | 情報処理システム、情報処理装置、監視装置、監視方法、及び、プログラム |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
-
2018
- 2018-09-21 SG SG11202002116YA patent/SG11202002116YA/en unknown
- 2018-09-21 WO PCT/US2018/052197 patent/WO2019060707A1/en unknown
- 2018-09-21 JP JP2020516662A patent/JP7203834B2/ja active Active
- 2018-09-21 EP EP24156669.4A patent/EP4374850A2/en not_active Withdrawn
- 2018-09-21 IL IL273384A patent/IL273384B2/en unknown
- 2018-09-21 TW TW107133293A patent/TW201919711A/zh unknown
- 2018-09-21 MA MA050266A patent/MA50266A/fr unknown
- 2018-09-21 US US16/138,158 patent/US20190111147A1/en not_active Abandoned
- 2018-09-21 KR KR1020207011137A patent/KR20200070254A/ko not_active Application Discontinuation
- 2018-09-21 CN CN201880075572.2A patent/CN111372610B/zh active Active
- 2018-09-21 AU AU2018335780A patent/AU2018335780A1/en active Pending
- 2018-09-21 CN CN202310589494.0A patent/CN117065043A/zh active Pending
- 2018-09-21 EP EP18783303.3A patent/EP3684412B1/en active Active
- 2018-09-21 CA CA3075896A patent/CA3075896A1/en active Pending
-
2021
- 2021-12-13 US US17/549,327 patent/US20220202947A1/en not_active Abandoned
-
2022
- 2022-12-27 JP JP2022209534A patent/JP2023036874A/ja not_active Ceased
-
2023
- 2023-07-18 IL IL304551A patent/IL304551A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010030670A2 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
| WO2017004026A1 (en) * | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Anti-cd 123 antibodies and conjugates and derivatives thereof |
Non-Patent Citations (3)
| Title |
|---|
| BERTOLOTTI-CIARLET A ET AL,, IMPACT OF METHIONINE OXIDATION ON THE BINDING OF HUMAN IGG1 TO FCRN AND FCGAMMA RECEPTORS, 1 May 2009 (2009-05-01) * |
| LAM X M ET AL,, ANTIOXIDANTS FOR PREVENTION OF METHIONINE OXIDATION IN RECOMBINANT MONOCLONAL ANTIBODY HER2, 1 November 1997 (1997-11-01) * |
| WHITEMAN K R ET AL,, IMGN779: A CD33-TARGETED ANTIBODY-DRUG CONJUGATE (ADC) UTILIZING A NOVEL DNA ALKYLATOR, DGN462, IS HIGHLY ACTIVE IN VITRO AGAINST PRIMARY PATIENT AML CELLS AND IN VIVO AGAINST AML XENOGRAFTS IN MICE, 1 June 2014 (2014-06-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202002116YA (en) | 2020-04-29 |
| US20190111147A1 (en) | 2019-04-18 |
| JP7203834B2 (ja) | 2023-01-13 |
| KR20200070254A (ko) | 2020-06-17 |
| WO2019060707A1 (en) | 2019-03-28 |
| TW201919711A (zh) | 2019-06-01 |
| IL273384B1 (en) | 2023-08-01 |
| CN117065043A (zh) | 2023-11-17 |
| EP3684412A1 (en) | 2020-07-29 |
| CN111372610B (zh) | 2023-05-30 |
| US20220202947A1 (en) | 2022-06-30 |
| RU2020113280A (ru) | 2021-10-25 |
| CN111372610A (zh) | 2020-07-03 |
| CA3075896A1 (en) | 2019-03-28 |
| JP2020534326A (ja) | 2020-11-26 |
| MA50266A (fr) | 2020-07-29 |
| IL273384A (en) | 2020-05-31 |
| RU2020113280A3 (ru) | 2022-04-11 |
| EP3684412B1 (en) | 2024-02-14 |
| JP2023036874A (ja) | 2023-03-14 |
| AU2018335780A1 (en) | 2020-03-26 |
| IL304551A (en) | 2023-09-01 |
| EP4374850A2 (en) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020111583A (ja) | 抗ｃｓ１抗体および抗体薬結合体 | |
| US8309094B2 (en) | Antibody-drug conjugates | |
| TWI735352B (zh) | 自行穩定之接合劑共軛物 | |
| Gébleux et al. | Antibody-drug conjugates: Current status and future perspectives | |
| ES2788864T3 (es) | Conjugados de anticuerpo-fármaco e inmunotoxinas | |
| JP6522806B2 (ja) | 抗体デュオカルマイシン薬物複合体を含む組成物 | |
| IL273384B2 (en) | Methods to prevent methionine oxidation in immune conjugates | |
| RU2006144958A (ru) | Химические линкеры и их конъюгаты | |
| RU2022101392A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP2024501894A (ja) | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 | |
| JP2024133544A (ja) | 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法 | |
| US20230330258A1 (en) | Conjugates comprising a phosphorus (v) and a drug moiety | |
| JPWO2020223221A5 (ru) | ||
| US20230355792A1 (en) | Methods of improving the therapeutic index | |
| RU2023123071A (ru) | Способы предотвращения окисления метионина в иммуноконъюгатах | |
| Pandey et al. | Antibody–drug conjugate: Emerging trend for targeted treatment | |
| KR20240100415A (ko) | 인(v) 및 캄프토테신 모이어티를 포함하는 접합체 | |
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты |